JUN and neoplasm: For example, in clinical trials of c-Jun-overexpressing CAR-T cells 51, 96, while c-Jun boosts CAR-T cytotoxicity, it also increases cytokine secretion and activation signals, potentially leading to CRS and unintended damage to normal tissues expressing low levels of tumor-associated antigens.